National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom

Ameet Bakhai, Marcus D. Flather, Julian R. Collinson, Warren Stevens, Charles Normand, Evo Alemao, Robbin Itzler, Rami Ben-Joseph

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Acute coronary syndromes without ST elevation are a major health and economic burden. Treatments such as glycoprotein IIb/IIIa antagonists like tirofiban reduce the risk of complications but the cost impact of these agents including cost offsets of avoiding complications are needed particularly in Europe.
Original languageEnglish
Pages (from-to)163-172
Number of pages10
JournalInternational Journal of Cardiology
Issue number2-3
Publication statusPublished - Oct 2003


  • Aged
  • Angina, Unstable
  • Anticoagulants
  • Cardiac Catheterization
  • Coronary Angiography
  • Coronary Disease
  • Electrocardiography
  • Female
  • Great Britain
  • Hemorrhage
  • Heparin
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Patient Admission
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Predictive Value of Tests
  • Prospective Studies
  • Risk Factors
  • Sensitivity and Specificity
  • Syndrome
  • Treatment Outcome
  • Tyrosine

Cite this